Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC W Schütte,F Barlesi,K Park,F Ciardiello,J Pawel,S Gadgeel,T Hida,D Kowalski,M Cobo Dols,D Cortinovis,J Leach,J Polikoff, DR Gandara,C Barrios,DS Chen,P He,M Ballinger,D Waterkamp,A Sandler,A RittmeyerPneumologie(2017)引用 0|浏览44暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要